Member Info for CHELSEA7

AT 7.80

Up to 7.52 from 7.35

7.50/8

Twice................40k and 13k..............Good ending

Aim (big)

Shuffling the pack again

Up to 120k 7.35

To over 240k 7.21

Needing more shares

Taking 240k+ at one price now 7.4p

7.2/8

A couple of sells to oil the wheels, around 160k

+ 8.57%

Sure has dragon.

Bid still rising, up to 150k 7.53, to 240k and over 7.45.

HNY Dragon

Buys 260k

Sells 20k

7.30/8 + 9.29%.......................16 Trades

Twice noww

Taking 100k odd at 7.45.............down to 7.45 for 240k+, a bit less than that.

Closed Friday at 7.01

7.30/8

Last buy 7.97

All buys..................4 Trades

Moving on nicely too, at close on Friday the bid ticked up to 7 with dummy sells at 7.01.

Today for 240k+ shares MMs will pay 7.17

On a MerryMonday Morning 7/7.50

With Full Ask 7.50 Paid now for 66,666

Yep, it is, and it was just on 13th December we the SP was 4.90 and just two weeks later 27th December 7/7.15,given a UT or two.

Sounds even better when we say the M/Cap has soared from £22m-£33m in that two weeks too.

I think there are quite a few of us urging the share to a M/Cap between £65/70m where many an average lies.

Just makes you wonder the staggering workload Lindy and her crew undertake. Imagine how many different responsibilities she holds, and the skill sets needed to delegate to Senior Management, not even to mention her duties to the University of Nottingham.

Just another reason why I believe we could well be under the radar of much larger companies in taking the platforms further than we could ever imagine and I guess it is frustrating to think that no patients as yet are being treated. However, the possibilities of having three trials running in 2020 seems not be lost in the performance of the share price at the moment.With Vulpes increasing their holding to at least 17.3% is such a big positive at this time, and as ever they know a lot more than we do!!

So really looking forward to next year, yes another ""pivotal"" year, but somehow it feels very different to the others. The scope for good news is huge, such an important factor in this market, we can only hope Lady Luck is with us and timelines are met. Not too much to ask for?? is it??

Onwards, forwards into 2020 and so good to crack 7p at the third attempt, and hoping we can keep the momentum going, consolidate and get some cracking news in January. Dreams, dreams, dreams and time for mine now. GN

Spurred on by Bermudas post, and seeking to understand nano particles/delivery in Cancer Immunotherapy, I found this article which I found understandable, easy to the eye and feel it has left me much the wiser. A good read.....................

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158870/

Abstract
Tumor glycans constitute attractive targets for therapeutic antibodies. The sialylated glycocalyx plays a prominent role in cancer progression and immune evasion. Here we describe the characterization of the monoclonal antibody, FG129, which targets tumor-associated sialylated glycan and demonstrate its potential for multimodal cancer therapy. FG129, obtained through BALB/c mouse immunizations with liposomes containing membrane glycan extracts from the colorectal cancer cell line LS180, is a mIgG1?, that targets sialyl-di-Lewisa-containing glycoproteins. FG129, as well as its chimeric human IgG1 variant, CH129, bind with nanomolar functional affinity to a range of colorectal, pancreatic and gastric cancer cell lines. FG129 targets 74% (135/182) of pancreatic, 50% (46/92) of gastric, 36% (100/281) of colorectal, 27% (89/327) of ovarian and 21% (42/201) of non-small cell lung cancers, by immunohistochemistry. In our pancreatic cancer cohort, high FG129 glyco-epitope expression was significantly associated with poor prognosis (p=0.004). Crucially, the glyco-epitope displays limited normal tissue distribution, with FG129 binding weakly to a small percentage of cells within gallbladder, ileum, liver, oesophagus, pancreas, and thyroid tissues. Owing to glyco-epitope internalization, we validated payload delivery by CH129 through monomethyl auristatin E (MMAE) or maytansinoid (DM1 and DM4) conjugation. All three CH129 drug conjugates killed high-binding colorectal and pancreatic cancer cell lines with (sub)nanomolar potency, coinciding with significant in vivo xenograft tumor control by CH129-vcMMAE. CH129, with its restricted normal tissue distribution, avid tumor binding and efficient payload delivery, is a promising candidate for the treatment of sialyl-di-Lewisa expressing solid tumors, as an ADC or as an alternative cancer immunotherapy modality.

Received March 4, 2019.
Revision received October 25, 2019.
Accepted December 9, 2019.
Copyright ©2019, American Association for Cancer Research.

Silvana T Tivadar, Richard S McIntosh, Jia Xin Chua, Robert Moss, Tina Parsons, Abed M. Zaitoun, Srinivasan Madhusudan, Lindy G Durrant and Mireille Vankemmelbek

Morning Guys and Morning Bermuda, if you can Bermuda (and others) translate that as best you can so as we cam all benefit to the maximum of what seems like a very exciting study. Thanks.